Inicio / Hematología / Abstracts de hematología / A distinct immunophenotype identifies a subset of NPM1‐mutated AML with TET2 or IDH1/2 mutations and improved outcome

A distinct immunophenotype identifies a subset of NPM1‐mutated AML with TET2 or IDH1/2 mutations and improved outcome

0 / 5 (0 votos)
A distinct immunophenotype identifies a subset of NPM1‐mutated AML with TET2 or IDH1/2 mutations and improved outcome

American Jornal of Hematology

Fecha de publicación: 23 December 2017

DOI: https://doi.org/10.1002/ajh.25018

Autores: Emily F. Mason, Frank C. Kuo, Robert P. Hasserjian, Adam C. Seegmiller, Olga Pozdnyakova

Background: Recent work has identified distinct molecular subgroups of acute myeloid leukemia (AML) with implications for disease classification and prognosis. NPM1 is one of the most common recurrently mutated genes in AML. NPM1 mutations often co‐occur with FLT3‐ITDs and mutations in genes regulating DNA methylation, such as DNMT3ATET2, and IDH1/2. It remains unclear whether these genetic alterations are associated with distinct immunophenotypic findings or affect prognosis.

SEGUIR LEYENDO

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.